Gain Therapeutics, Inc.
GANX
$1.80
$0.063.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 0.00 | 55.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 0.00 | 55.20K |
| Cost of Revenue | 12.94M | 13.75M | 13.73M | 13.68M | 13.97M |
| Gross Profit | -12.94M | -13.75M | -13.73M | -13.68M | -13.91M |
| SG&A Expenses | 9.63M | 9.56M | 10.24M | 10.24M | 10.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.35M | 21.43M | 21.85M | 21.40M | 22.31M |
| Operating Income | -20.35M | -21.43M | -21.85M | -21.40M | -22.25M |
| Income Before Tax | -19.87M | -21.32M | -21.54M | -21.06M | -22.19M |
| Income Tax Expenses | 536.80K | 46.60K | 57.10K | 82.50K | 79.30K |
| Earnings from Continuing Operations | -20.41 | -21.37 | -21.60 | -21.14 | -22.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.41M | -21.37M | -21.60M | -21.14M | -22.27M |
| EBIT | -20.35M | -21.43M | -21.85M | -21.40M | -22.25M |
| EBITDA | -20.32M | -21.39M | -21.82M | -21.37M | -22.22M |
| EPS Basic | -0.95 | -1.13 | -1.33 | -1.53 | -1.74 |
| Normalized Basic EPS | -0.58 | -0.71 | -0.83 | -0.95 | -1.08 |
| EPS Diluted | -0.95 | -1.13 | -1.33 | -1.53 | -1.74 |
| Normalized Diluted EPS | -0.58 | -0.71 | -0.83 | -0.95 | -1.08 |
| Average Basic Shares Outstanding | 91.43M | 78.75M | 64.92M | 58.09M | 52.04M |
| Average Diluted Shares Outstanding | 91.43M | 78.75M | 64.92M | 58.09M | 52.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |